Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
- AbbVie Files Viekirax for Genotype 2 Hepatitis C
December 18, 2015
- Opdivo Gets Lung Cancer Indication in Japan: Ono
December 18, 2015
- Takeda to Divest Respiratory Biz to AstraZeneca
December 17, 2015
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Takeda, Kyoto University Kick Off iPS Projects Targeting 6 Diseases
December 16, 2015
- LEO Pharma “Eager to Do More” after Astellas Deal to Expand Globally: CEO
December 16, 2015
- JPO Says Patents for Alimta Vitamin Therapy Valid until 2021
December 16, 2015
- Mitsubishi Tanabe Gains Exclusive Rights to Akebia’s Anemia Drug in Asia
December 16, 2015
- Mundipharma Poised to Expand Japan Operations by Tapping Isodine Brand: Asia Head
December 15, 2015
- Daiichi Sankyo Looking for a Partner to Codevelop GPR119 Agonist: CEO Nakayama
December 15, 2015
- GSK to Supply Tenozet by Imports from Gilead
December 15, 2015
- Astellas Joins Hands with US Biopharma Bellicum on Cancer Cell Therapy
December 14, 2015
- Novartis Submits Business Improvement Plan over ADR Reporting Delays
December 14, 2015
- ASKA to Launch Authorized Generics of Unisia in March
December 14, 2015
- Ono Files Opdivo for Kidney Cancer, Third Indication in Japan
December 14, 2015
- Mundipharma to Link Up with Shionogi on Isodine Brand, Dissolve Ties with Meiji Seika Pharma
December 11, 2015
- M&As among Generic Makers Would Reap No Benefits: Sawai President
December 11, 2015
- Sumitomo Dainippon to Launch 3 Pivotal Trials for Napabucasin in FY2015, Postpone BBI503 Program
December 10, 2015
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…